beyond our product candidates , we continue to advance and build our discovery pipeline . we are discovering and developing next-generation immunotherapies by leveraging our translational science platform to systematically and comprehensively interrogate cell types within the tumor microenvironment . our broad discovery pipeline includes multiple programs targeting myeloid cells such as macrophages , t regulatory cells and non-immune cells , such as stromal cells . we believe that the use of our translational science platform to efficiently identify novel immuno-oncology targets and advance them from discovery to investigational new drug application , or ind , stage is a sustainable approach that we plan to continually apply across our broad discovery pipeline and target selection process . in august 2020 , we entered into an agreement to exclusively license jtx-1811 to gilead sciences , inc. , or gilead . jtx-1811 is the most recent product candidate to emerge from our translational science platform , and , is a monoclonal antibody that is designed to selectively deplete t regulatory cells in the tumor microenvironment , or tme , by targeting a receptor called ccr8 , which is preferentially expressed on intra-tumoral t regulatory cells . pursuant to our exclusive license agreement with gilead , or the gilead license agreement , we granted gilead a worldwide license to develop , manufacture and commercialize jtx-1811 and certain derivatives thereof , as well as backup antibodies defined within the agreement . concurrently with the license agreement , we entered into a stock purchase agreement with gilead , or the stock purchase agreement , and a registration rights agreement . 54 under the terms of the gilead license agreement and stock purchase agreement , gilead paid us a one-time , non-refundable upfront payment of $ 85.0 million and $ 35.0 million to purchase 5,539,727 shares of our common stock pursuant to the stock purchase agreement . under the terms of the gilead license agreement , we will advance jtx-1811 until the clearance of an ind application or an earlier date specified by gilead , at which time the program will be transitioned to gilead . we are entitled to receive payments from gilead upon the achievement of specified clinical , regulatory and sales milestones , including potential clinical development and regulatory milestone payments up to an aggregate total of $ 510.0 million and potential sales milestone payments up to an aggregate total of $ 175.0 million . we are also eligible to receive tiered royalty payments based on a percentage of annual worldwide net sales ranging from the high-single digits to mid-teens , based on future annual net sales of licensed products , on a licensed product-by-licensed product and country-by-country basis . on july 22 , 2019 , we entered into an exclusive license agreement with celgene , or the celgene license agreement , granting celgene a worldwide and exclusive license to develop , manufacture and commercialize jtx-8064 and certain derivatives thereof , as well as any antibody or other biologic controlled by us that is specifically directed to the lilrb2 receptor . under the terms of the celgene license agreement , celgene paid us a one-time , non-refundable upfront payment of $ 50.0 million . celgene was subsequently acquired by bristol myers squibb , or bms , in november 2019 and the celgene license agreement was terminated effective june 3 , 2020. we now have sole worldwide rights to jtx-8064 , and all of our intellectual property rights pertaining to jtx-8064 and licensed to celgene were reacquired by us . in july 2016 , we entered into a master research and collaboration agreement , or the celgene collaboration agreement , and a series b-1 preferred stock purchase agreement with celgene . under the terms of these agreements , we received a $ 225.0 million upfront cash payment and $ 36.1 million from the sale of 10,448,100 shares of our series b-1 convertible preferred stock , which shares converted into 2,831,463 shares of common stock upon the completion of our initial public offering , or ipo , in 2017. we terminated the celgene collaboration agreement concurrently with entry into the celgene license agreement . since inception , our operations have focused on organizing and staffing our company , business planning , raising capital , developing our translational science platform and conducting research , preclinical studies and clinical trials . we do not have any products approved for sale . we are subject to a number of risks comparable to those of other similar companies , including dependence on key individuals ; the need to develop commercially viable products ; competition from other companies , many of which are larger and better capitalized ; and the need to obtain adequate additional financing to fund the development of our products . we have funded our operations primarily through proceeds received from public offerings and private placements of our stock totaling $ 298.5 million and up-front payments from our celgene and gilead collaboration and license agreements totaling $ 360.0 million . due to our significant research and development expenditures , we have accumulated substantial losses since our inception . as of december 31 , 2020 , we had an accumulated deficit of $ 151.0 million . we expect to incur substantial additional losses in the future as we expand our research and development activities . the spread of covid-19 during 2020 has caused an economic downturn on a global scale . as of february 25 , 2021 , we have not experienced a significant financial impact directly related to the covid-19 pandemic but have experienced some disruptions to clinical operations and to our supply chain . as the pandemic continues to unfold , the extent of its effect on our operational and financial performance will depend in large part on future developments , which can not be predicted with confidence at this time . story_separator_special_tag the evaluation of uncertain tax positions is based on factors , including , but not limited to , changes in the law , the measurement of tax positions taken or expected to be taken in tax returns , the effective settlement of matters subject to audit , new audit activity and changes in facts or circumstances related to a tax position . recent accounting pronouncements see note 2 to our consolidated financial statements included within part iv , item 15 of this annual report on form 10-k for a description of recent accounting pronouncements applicable to our business . results of operations comparison of the years ended december 31 , 2020 and 2019 the following table summarizes our results of operations for the years ended december 31 , 2020 and 2019 : replace_table_token_2_th license and collaboration revenue for the year ended december 31 , 2020 , we recognized $ 62.3 million of license revenue under the gilead license agreement entered into in october 2020. for the year ended december 31 , 2019 , we recognized $ 147.9 million of license and collaboration revenue , which was comprised of $ 50.0 million of license revenue under the celgene license agreement and $ 97.9 million of collaboration revenue under the celgene collaboration agreement . the celgene collaboration agreement was terminated effective july 22 , 2019 , at which time all remaining deferred revenue was recognized as we had no further performance obligations . 59 research and development expenses the following table summarizes our research and development expenses for the years ended december 31 , 2020 and 2019 : replace_table_token_3_th research and development expenses increased by $ 11.6 million from $ 67.1 million for the year ended december 31 , 2019 to $ 78.7 million for the year ended december 31 , 2020. the increase in research and development expenses was primarily attributable to : $ 7.9 million of increased external clinical and regulatory costs primarily attributable to our select clinical trial which commenced in 2020 ; $ 3.2 million of increased external research and development costs primarily attributable to ind-enabling expenses related to jtx-1811 , partially offset by reduced expenses related to jtx-8064 incurred during the year ended december 31 , 2020 ; $ 2.9 million of increased employee compensation costs primarily attributable to increased headcount , merit and bonus expense ; partially offset by $ 0.9 million of decreased other research costs primarily attributable to reduced travel expenses resulting from covid-19 travel limitations ; and $ 0.8 million of decreased lab consumables costs . general and administrative expenses the following table summarizes our general and administrative expenses for the years ended december 31 , 2020 and 2019 : replace_table_token_4_th general and administrative expenses increased by $ 0.8 million from $ 27.9 million for the year ended december 31 , 2019 to $ 28.8 million for the year ended december 31 , 2020. the increase in general and administrative expenses was primarily attributable to $ 1.5 million of increased employee compensation costs related to increased merit and bonus expense for the year ended december 31 , 2020. other income , net other income , net , decreased by $ 2.8 million from $ 4.1 million for the year ended december 31 , 2019 to $ 1.3 million for the year ended december 31 , 2020. the decrease in other income , net is attributable to reduced interest rates due to current market conditions . 60 liquidity and capital resources sources of liquidity we have funded our operations primarily through proceeds received from public offerings and private placements of our stock totaling $ 298.5 million and up-front payments from our celgene and gilead collaboration and license agreements totaling $ 360.0 million . as of december 31 , 2020 , we had cash , cash equivalents and investments of $ 213.2 million . on december 17 , 2019 , we entered into a sales agreement with cowen and company , llc , or cowen , pursuant to which we offered and sold shares of our common stock with an aggregate offering price of up to $ 50.0 million under the atm offering . the sales agreement provides that cowen will be entitled to a sales commission equal to 3.0 % of the gross sales price per share of all shares sold under the atm offering . as of december 31 , 2020 , we had sold an aggregate of 2,522,121 shares under the atm offering at an average price of $ 7.47 per share for net proceeds of $ 18.0 million after deducting sales commissions and offering expenses , of which $ 14.5 million was received during the year ended december 31 , 2020. in january 2021 , we sold an aggregate of 3,156,200 shares at an average price of $ 9.87 per share for net proceeds of $ 30.2 million . consequently , we have completed the sale of all available amounts under the atm offering , of which three investors account for $ 43.1 million of all funds raised ( see note 16 to our consolidated financial statements included within part iv , item 15 of this annual report on form 10-k ) . funding requirements our plan of operation is to continue implementing our business strategy , the research and development of our current product candidates , our preclinical development activities , the expansion of our research pipeline and the enhancement of our internal research and development capabilities . due to the inherently unpredictable nature of preclinical and clinical development and given the early stage of our programs and product candidates , we can not reasonably estimate the costs we will incur and the timelines that will be required to complete development , obtain marketing approval , and commercialize our products , if and when approved . for the same reasons , we are also unable to predict when , if ever , we will generate revenue from product sales or whether , or when , if ever , we may

cash flows the following table provides information regarding our cash flows for the years ended december 31 , 2020 and 2019 : replace_table_token_5_th cash used in operating activities net cash used in operating activities for the year ended december 31 , 2020 was $ 27.8 million , compared to net cash used in operating activities of $ 30.1 million for the year ended december 31 , 2019. cash used in operating activities decreased by $ 2.3 million primarily due to $ 62.3 million in revenue recognized under the gilead license agreement in 2020 , partially offset by $ 50.0 million in revenue recognized under the celgene license agreement during 2019 and increased operating expenses during the year ended december 31 , 2020. cash provided by investing activities net cash provided by investing activities for the year ended december 31 , 2020 was $ 51.3 million , compared to net cash provided by investing activities of $ 31.4 million for the year ended december 31 , 2019. cash provided by investing activities increased by $19.9 million as cash was reinvested into cash equivalents , as opposed to other short-term and long-term investments , due to current market conditions during the year ended december 31 , 2020. proceeds received from maturities and sales of investments were either re-invested or used to fund operations .


 Write a concise suspicious activity report of the following text delimited by triple backquotes. Return your response as a formal report which covers the key points highlighting the location,dates,entity names and account holder information in chronological order of the text.
     ```cash flows the following table provides information regarding our cash flows for the years ended december 31 , 2020 and 2019 : replace_table_token_5_th cash used in operating activities net cash used in operating activities for the year ended december 31 , 2020 was $ 27.8 million , compared to net cash used in operating activities of $ 30.1 million for the year ended december 31 , 2019. cash used in operating activities decreased by $ 2.3 million primarily due to $ 62.3 million in revenue recognized under the gilead license agreement in 2020 , partially offset by $ 50.0 million in revenue recognized under the celgene license agreement during 2019 and increased operating expenses during the year ended december 31 , 2020. cash provided by investing activities net cash provided by investing activities for the year ended december 31 , 2020 was $ 51.3 million , compared to net cash provided by investing activities of $ 31.4 million for the year ended december 31 , 2019. cash provided by investing activities increased by $19.9 million as cash was reinvested into cash equivalents , as opposed to other short-term and long-term investments , due to current market conditions during the year ended december 31 , 2020. proceeds received from maturities and sales of investments were either re-invested or used to fund operations .
```    
 Suspicious Activity Report : beyond our product candidates , we continue to advance and build our discovery pipeline . we are discovering and developing next-generation immunotherapies by leveraging our translational science platform to systematically and comprehensively interrogate cell types within the tumor microenvironment . our broad discovery pipeline includes multiple programs targeting myeloid cells such as macrophages , t regulatory cells and non-immune cells , such as stromal cells . we believe that the use of our translational science platform to efficiently identify novel immuno-oncology targets and advance them from discovery to investigational new drug application , or ind , stage is a sustainable approach that we plan to continually apply across our broad discovery pipeline and target selection process . in august 2020 , we entered into an agreement to exclusively license jtx-1811 to gilead sciences , inc. , or gilead . jtx-1811 is the most recent product candidate to emerge from our translational science platform , and , is a monoclonal antibody that is designed to selectively deplete t regulatory cells in the tumor microenvironment , or tme , by targeting a receptor called ccr8 , which is preferentially expressed on intra-tumoral t regulatory cells . pursuant to our exclusive license agreement with gilead , or the gilead license agreement , we granted gilead a worldwide license to develop , manufacture and commercialize jtx-1811 and certain derivatives thereof , as well as backup antibodies defined within the agreement . concurrently with the license agreement , we entered into a stock purchase agreement with gilead , or the stock purchase agreement , and a registration rights agreement . 54 under the terms of the gilead license agreement and stock purchase agreement , gilead paid us a one-time , non-refundable upfront payment of $ 85.0 million and $ 35.0 million to purchase 5,539,727 shares of our common stock pursuant to the stock purchase agreement . under the terms of the gilead license agreement , we will advance jtx-1811 until the clearance of an ind application or an earlier date specified by gilead , at which time the program will be transitioned to gilead . we are entitled to receive payments from gilead upon the achievement of specified clinical , regulatory and sales milestones , including potential clinical development and regulatory milestone payments up to an aggregate total of $ 510.0 million and potential sales milestone payments up to an aggregate total of $ 175.0 million . we are also eligible to receive tiered royalty payments based on a percentage of annual worldwide net sales ranging from the high-single digits to mid-teens , based on future annual net sales of licensed products , on a licensed product-by-licensed product and country-by-country basis . on july 22 , 2019 , we entered into an exclusive license agreement with celgene , or the celgene license agreement , granting celgene a worldwide and exclusive license to develop , manufacture and commercialize jtx-8064 and certain derivatives thereof , as well as any antibody or other biologic controlled by us that is specifically directed to the lilrb2 receptor . under the terms of the celgene license agreement , celgene paid us a one-time , non-refundable upfront payment of $ 50.0 million . celgene was subsequently acquired by bristol myers squibb , or bms , in november 2019 and the celgene license agreement was terminated effective june 3 , 2020. we now have sole worldwide rights to jtx-8064 , and all of our intellectual property rights pertaining to jtx-8064 and licensed to celgene were reacquired by us . in july 2016 , we entered into a master research and collaboration agreement , or the celgene collaboration agreement , and a series b-1 preferred stock purchase agreement with celgene . under the terms of these agreements , we received a $ 225.0 million upfront cash payment and $ 36.1 million from the sale of 10,448,100 shares of our series b-1 convertible preferred stock , which shares converted into 2,831,463 shares of common stock upon the completion of our initial public offering , or ipo , in 2017. we terminated the celgene collaboration agreement concurrently with entry into the celgene license agreement . since inception , our operations have focused on organizing and staffing our company , business planning , raising capital , developing our translational science platform and conducting research , preclinical studies and clinical trials . we do not have any products approved for sale . we are subject to a number of risks comparable to those of other similar companies , including dependence on key individuals ; the need to develop commercially viable products ; competition from other companies , many of which are larger and better capitalized ; and the need to obtain adequate additional financing to fund the development of our products . we have funded our operations primarily through proceeds received from public offerings and private placements of our stock totaling $ 298.5 million and up-front payments from our celgene and gilead collaboration and license agreements totaling $ 360.0 million . due to our significant research and development expenditures , we have accumulated substantial losses since our inception . as of december 31 , 2020 , we had an accumulated deficit of $ 151.0 million . we expect to incur substantial additional losses in the future as we expand our research and development activities . the spread of covid-19 during 2020 has caused an economic downturn on a global scale . as of february 25 , 2021 , we have not experienced a significant financial impact directly related to the covid-19 pandemic but have experienced some disruptions to clinical operations and to our supply chain . as the pandemic continues to unfold , the extent of its effect on our operational and financial performance will depend in large part on future developments , which can not be predicted with confidence at this time . story_separator_special_tag the evaluation of uncertain tax positions is based on factors , including , but not limited to , changes in the law , the measurement of tax positions taken or expected to be taken in tax returns , the effective settlement of matters subject to audit , new audit activity and changes in facts or circumstances related to a tax position . recent accounting pronouncements see note 2 to our consolidated financial statements included within part iv , item 15 of this annual report on form 10-k for a description of recent accounting pronouncements applicable to our business . results of operations comparison of the years ended december 31 , 2020 and 2019 the following table summarizes our results of operations for the years ended december 31 , 2020 and 2019 : replace_table_token_2_th license and collaboration revenue for the year ended december 31 , 2020 , we recognized $ 62.3 million of license revenue under the gilead license agreement entered into in october 2020. for the year ended december 31 , 2019 , we recognized $ 147.9 million of license and collaboration revenue , which was comprised of $ 50.0 million of license revenue under the celgene license agreement and $ 97.9 million of collaboration revenue under the celgene collaboration agreement . the celgene collaboration agreement was terminated effective july 22 , 2019 , at which time all remaining deferred revenue was recognized as we had no further performance obligations . 59 research and development expenses the following table summarizes our research and development expenses for the years ended december 31 , 2020 and 2019 : replace_table_token_3_th research and development expenses increased by $ 11.6 million from $ 67.1 million for the year ended december 31 , 2019 to $ 78.7 million for the year ended december 31 , 2020. the increase in research and development expenses was primarily attributable to : $ 7.9 million of increased external clinical and regulatory costs primarily attributable to our select clinical trial which commenced in 2020 ; $ 3.2 million of increased external research and development costs primarily attributable to ind-enabling expenses related to jtx-1811 , partially offset by reduced expenses related to jtx-8064 incurred during the year ended december 31 , 2020 ; $ 2.9 million of increased employee compensation costs primarily attributable to increased headcount , merit and bonus expense ; partially offset by $ 0.9 million of decreased other research costs primarily attributable to reduced travel expenses resulting from covid-19 travel limitations ; and $ 0.8 million of decreased lab consumables costs . general and administrative expenses the following table summarizes our general and administrative expenses for the years ended december 31 , 2020 and 2019 : replace_table_token_4_th general and administrative expenses increased by $ 0.8 million from $ 27.9 million for the year ended december 31 , 2019 to $ 28.8 million for the year ended december 31 , 2020. the increase in general and administrative expenses was primarily attributable to $ 1.5 million of increased employee compensation costs related to increased merit and bonus expense for the year ended december 31 , 2020. other income , net other income , net , decreased by $ 2.8 million from $ 4.1 million for the year ended december 31 , 2019 to $ 1.3 million for the year ended december 31 , 2020. the decrease in other income , net is attributable to reduced interest rates due to current market conditions . 60 liquidity and capital resources sources of liquidity we have funded our operations primarily through proceeds received from public offerings and private placements of our stock totaling $ 298.5 million and up-front payments from our celgene and gilead collaboration and license agreements totaling $ 360.0 million . as of december 31 , 2020 , we had cash , cash equivalents and investments of $ 213.2 million . on december 17 , 2019 , we entered into a sales agreement with cowen and company , llc , or cowen , pursuant to which we offered and sold shares of our common stock with an aggregate offering price of up to $ 50.0 million under the atm offering . the sales agreement provides that cowen will be entitled to a sales commission equal to 3.0 % of the gross sales price per share of all shares sold under the atm offering . as of december 31 , 2020 , we had sold an aggregate of 2,522,121 shares under the atm offering at an average price of $ 7.47 per share for net proceeds of $ 18.0 million after deducting sales commissions and offering expenses , of which $ 14.5 million was received during the year ended december 31 , 2020. in january 2021 , we sold an aggregate of 3,156,200 shares at an average price of $ 9.87 per share for net proceeds of $ 30.2 million . consequently , we have completed the sale of all available amounts under the atm offering , of which three investors account for $ 43.1 million of all funds raised ( see note 16 to our consolidated financial statements included within part iv , item 15 of this annual report on form 10-k ) . funding requirements our plan of operation is to continue implementing our business strategy , the research and development of our current product candidates , our preclinical development activities , the expansion of our research pipeline and the enhancement of our internal research and development capabilities . due to the inherently unpredictable nature of preclinical and clinical development and given the early stage of our programs and product candidates , we can not reasonably estimate the costs we will incur and the timelines that will be required to complete development , obtain marketing approval , and commercialize our products , if and when approved . for the same reasons , we are also unable to predict when , if ever , we will generate revenue from product sales or whether , or when , if ever , we may

